8-K: STAAR Surgical Board Overhaul, CEO Farrell Steps Down

STAAR Surgical announces a significant board restructuring and CEO Stephen Farrell's departure, following a cooperation agreement with major shareholder Broadwood Partners.

Summary

• STAAR Surgical Company entered into a Cooperation Agreement with Broadwood Partners, L.P. on January 14, 2026.
• The Board of Directors increased from six to seven members.
• Stephen C. Farrell (CEO) and Elizabeth Yeu, MD resigned from the Board, effective January 14, 2026.
• Neal C. Bradsher, Richard T. LeBuhn, and Christopher Min Fang Wang were appointed to the Board.
• Stephen C. Farrell's service as Chief Executive Officer will terminate on January 31, 2026, or an earlier date determined by the Board.
• The Company will nominate the new directors for election at the 2026 annual meeting, and the Board size will not exceed seven until the 2027 annual meeting.
• STAAR Surgical will reimburse Broadwood Partners up to $6 million, Yunqi Capital up to $1 million, and Defender Capital up to $25,000 for certain expenses.
• Broadwood Partners agreed to standstill provisions until June 18, 2026, including not requesting a special meeting of stockholders.
• The Company is currently non-compliant with NASDAQ Listing Rule 5605, which requires at least three independent directors on the Audit Committee, due to Dr. Yeu's resignation. The Company intends to use the cure period.
• Mr. Farrell's termination as CEO is considered "without cause," entitling him to 18 months of base salary and 18 months of insurance premium reimbursement, plus consulting fees of $45,000 per month for one year.
• Certain unvested restricted stock units (February 2026 vesting) will vest, while others are forfeited. Performance-based restricted stock units may be earned up to 140,100 units based on performance through the quarter ending July 3, 2026.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to significant leadership changes, including the CEO and Board Chair stepping down, and temporary NASDAQ non-compliance. While a cooperation agreement resolves immediate shareholder conflict and brings new expertise, the underlying reasons for such a drastic overhaul and the associated costs (severance, consulting fees) suggest challenges. The positive spin from new board members about future potential is noted, but the immediate implications are disruptive.

Positives

• Resolution of potential shareholder activism through a cooperation agreement with Broadwood Partners, the largest shareholder.
• Appointment of three new directors with expertise in public market investments, healthcare, and business in China, bringing fresh perspectives and long-term investor viewpoints.
• Neal Bradsher, Broadwood Founder and President, expressed commitment to enhancing profitability and driving sustainable, long-term value creation.
• Management comments indicate the company returned to profitability and cash flow generation in early 2025 under the outgoing CEO.

Negatives

• Departure of CEO Stephen C. Farrell and Board Chair Elizabeth Yeu, MD, indicating significant leadership changes.
• Temporary non-compliance with NASDAQ Listing Rule 5605 regarding the Audit Committee's independent director requirement.
• Significant severance and consulting payments to the outgoing CEO, including 18 months of base salary, 18 months of insurance premiums, and $45,000 per month for one year of consulting.

Risks

• Non-compliance with NASDAQ Listing Rule 5605, requiring the Audit Committee to have at least three independent directors, which could lead to delisting if not cured within the provided period.
• Leadership transition risks associated with the departure of the CEO and Board Chair, and the integration of new directors.
• Potential for disruption during the search for a new CEO and Board Chair.

Future Outlook

The renewed Board intends to make additional announcements regarding STAAR's next Chair and CEO in the near term. The new directors aim to enhance profitability and drive sustainable, long-term value creation. The company also plans to regain compliance with NASDAQ listing rules regarding its Audit Committee.

Management Comments

• "We welcome our new Board members, who bring to STAAR expertise with respect to relevant public market investments, healthcare, and business in China, as well as the perspectives of long-term investors and supporters of STAAR. We will work together to enhance profitability and drive sustainable, long-term value creation." Louis Silverman, STAAR director.
• "I am honored to join STAAR’s Board. The Company’s leading technology, strong financial position, and privileged market position provide it with the opportunity to achieve growth and profit margin expansion. As STAAR’s largest shareholder, Broadwood is committed to helping the Company realize its full potential." Neal C. Bradsher, Broadwood Founder and President.
• "I want to thank Liz Yeu for her early recognition of the advantages of the ICL over tissue removal refractive procedures. I want to thank Steve Farrell for leading STAAR out of a difficult situation in early 2025 and back to profitability and cash flow generation." Neal C. Bradsher.
• "I believe that the exit compensation package provided to Steve by the prior board was appropriate based on the conditions at the time." Neal C. Bradsher.

Industry Context

The changes at STAAR Surgical reflect increasing shareholder activism in the medical device sector, particularly from large institutional investors like Broadwood Partners and Yunqi Capital. The appointment of directors with strong financial and investment backgrounds, including expertise in the China market, suggests a strategic focus on optimizing financial performance and expanding in key international markets for implantable collamer lenses (ICLs).

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Significant impact due to major board and leadership changes, potentially leading to a new strategic direction focused on profitability and value creation. Broadwood Partners and Yunqi Capital, as major shareholders, gain increased representation.
• Employees: Potential impact from leadership transition, especially with the CEO's departure, which could lead to shifts in company culture or operational priorities.
• Customers: Unlikely direct immediate impact, but long-term strategic shifts could influence product development or market focus.
• Creditors: No direct impact mentioned, but improved governance and focus on profitability could indirectly strengthen the company's financial position.

Next Steps

• The Board will make additional announcements regarding STAAR's next Chair and CEO in the near term.
• The Company will work to regain compliance with NASDAQ Listing Rule 5605 regarding the Audit Committee's independent director requirement within the cure period.
• The Board will nominate the new directors for election at the 2026 annual meeting of stockholders.
• Stephen C. Farrell will provide consulting services to the Company for one year following his separation date.

Key Dates

Recommendation

The filing details a significant corporate governance overhaul, including the departure of the CEO and Board Chair, and the appointment of three new directors representing major shareholders. While this resolves immediate shareholder activism and brings in new expertise focused on profitability, the temporary NASDAQ non-compliance and the disruption of a leadership transition introduce uncertainty. The substantial severance package for the outgoing CEO also warrants attention. Investors should hold to observe the new board's strategic direction, the appointment of a new CEO, and the resolution of the NASDAQ compliance issue before making further investment decisions.

Keywords

STAAR Surgical, STAA, Board of Directors, CEO Change, Corporate Governance, Broadwood Partners, NASDAQ Compliance, Executive Compensation, Medical Devices, Ophthalmology, ICL, Vision Correction